Interview with Luxa Biotechnology Leadership: Promising Results of RPESC-RPE-4W for Dry AMD

Our CEO Dr. Keith Dionne, along with CSO Dr. Sally Temple and CMO Dr. Jeffrey Stern, recently spoke with a leading Korean healthcare media outlet, Daily Pharm. They discussed Luxa Biotechnology’s progress in developing a novel cell therapy for dry age-related macular degeneration (AMD). The article was published in Korean.

Here’s a brief summary for English speakers:

- Our investigational therapy, RPESC-RPE-4W, uses allogeneic adult retinal stem cells (RPESCs) to replace damaged RPE cells and restore vision — targeting the root cause of dry AMD.
- In our ongoing Phase 1/2a clinical trial, we recently shared Cohort 1 results at ARVO 2025. Six patients received a low dose (50,000 cells) of RPESC-RPE-4W:
• No serious adverse events, tumorigenicity, inflammation or epiretinal membrane formation.
• Encouraging early signs of vision improvement — patients with the lowest baseline vision gained an average of 22 letters on the ETDRS chart and the improvement was sustained over 12 months

The article  

https://www.dailypharm.com/Users/News/NewsView.html?ID=322822